Business / Finance

RSS

Polyplus-transfection grants research license to NIH for PEI-mediated transfection applications

Polyplus-transfection SA, a privately-held company developing innovative technologies for molecular and cellular biology, announces today that it has granted two agencies of the United States National Institutes of Health a non-exclusive, research license to use Polyethylenimine (PEI) for in vitro transfection applications. The two agencies are the National Institute of Allergy and Infectious Diseases and the National Cancer Institute.

17 Feb 2014

Advanced Accelerator Applications successfully completes capital increase of €41 million

Advanced Accelerator Applications, a fast growing international specialist in Molecular Nuclear Medicine (MNM), announced today that it had successfully completed a capital increase of €41 million.

17 Feb 2014

Novartis acquires CoStim Pharmaceuticals

MPM Capital and Atlas Venture announced today that portfolio company CoStim Pharmaceuticals, Inc. has been acquired by Novartis for an undisclosed amount. CoStim, founded in 2012 by MPM Managing Director Luke Evnin together with MPM Managing Director-Operations Robert Millman, is an emerging immuno-oncology company developing monoclonal antibody drugs that enable a patient's own immune system to better fight cancer.

17 Feb 2014

Horizon Discovery, Sirion Biotech ink supply and distribution agreement

Horizon Discovery, a leading provider of research tools to support translational genomics and the development of personalized medicines, today announced it has signed a supply and distribution agreement with Sirion Biotech GmbH.

17 Feb 2014

BMG Pharma signs agreement with Samyang Biopharmaceutical to market GelX in South Korea

BMG Pharma S.r.l. today is pleased to announce that it has signed an exclusive distribution agreement with Samyang Biopharmaceutical Corporation granting them the rights to promote, sell and market its novel mucositis management product GelX in the territory of South Korea.

17 Feb 2014

TPI announces financial results for second quarter fiscal year 2014

Tianyin Pharmaceutical Inc., a pharmaceutical company that specializes in the patented biopharmaceutical, modernized traditional Chinese medicine (mTCM), branded generics and active pharmaceutical ingredients (API) announced financial results for the second quarter fiscal year 2014.

14 Feb 2014

GNC Holdings reports consolidated revenue of $613.7 million in Q4 2013

GNC Holdings, Inc., a leading global specialty retailer of health and wellness products, today reported its financial results for the quarter and year-to-date period ended December 31, 2013.

13 Feb 2014

Fluidigm acquires DVS Sciences

Fluidigm Corp. today announced it has completed its acquisition of DVS Sciences, Inc. With the closing of the acquisition, Fluidigm adds a high-parameter single-cell protein analysis platform to its industry-leading single-cell genomics platforms to create a comprehensive portfolio of advanced technologies serving the rapidly growing single-cell genomics and proteomics markets.

13 Feb 2014

Healthways reports net loss of $5.3 million in Q4 2013

Ben R. Leedle, Jr., president and chief executive officer of Healthways, Inc., today announced financial results for the fourth quarter and year ended December 31, 2013. Total revenues for the quarter were $169.2 million compared with $175.2 million for the fourth quarter of 2012.

13 Feb 2014

Prothelia, University of Nevada, Reno and Alexion partner to develop Laminin-111 for MDC1A

Prothelia Incorporated and University of Nevada, Reno announce that they have entered into strategic agreements with Alexion for the development of Laminin-111, a patented experimental protein replacement therapy for merosin-deficient congenital muscular dystrophy (MDC1A), a life-threatening, ultra-rare disease caused by a genetic deficiency of the Laminin-211 protein.

13 Feb 2014

VCA Antech fourth quarter 2013 revenue increases 4.1% to $435.5 million

VCA Antech, Inc., a leading animal healthcare company in the United States and Canada, today reported financial results for the fourth quarter ended December 31, 2013, as follows: revenue increased 4.1% to $435.5 million and gross profit increased 6.9% to $87.5 million; operating income increased 155.0% to $45.9 million; net income increased 142.6% to $24.7 million and diluted earnings per common share increased 142.4% to $0.28.

13 Feb 2014

GE completes acquisition of API Healthcare

GE announced today it has completed the acquisition of API Healthcare, a healthcare workforce management solutions provider, headquartered in Hartford, WI.

13 Feb 2014

Bioanalytical Systems revenue increases 7.2% in first quarter of fiscal 2014

Bioanalytical Systems, Inc. today announced financial results for the first quarter of fiscal 2014.

13 Feb 2014

Global Healthcare REIT completes acquisition of Southern Tulsa Healthcare Center

Global Healthcare REIT, Inc. announced today that effective February 7, 2014, it completed the acquisition of its fourth facility.

13 Feb 2014

Agenus closes previously announced acquisition of 4-Antibody

Agenus Inc., a biopharmaceutical company developing novel immunotherapeutics, including a portfolio of checkpoint modulators (CPMs), anti-cancer vaccines and adjuvants, today completed the previously announced acquisition of 4-Antibody AG, a private European-based biopharmaceutical company.

13 Feb 2014

Quintiles' growth in service revenues increases 7.7% in Q4 2013

Quintiles Transnational Holdings Inc. today reported its financial results for the fourth quarter ended December 31, 2013.

13 Feb 2014

DataArt reports record revenue of $40 million for 2013

DataArt, a leading custom software development firm serving select industries, today announced a record revenue of $40M for 2013, a 25% annual growth, with over 90 new client wins.

13 Feb 2014

GenVec achieves third milestone for development of treatments for hearing and balance disorderstion

GenVec, Inc. (NASDAQ: GNVC) today announced that the company has achieved the third milestone in its collaboration with Novartis for the development of treatments for hearing and balance disorders.

13 Feb 2014

Lignol Energy signs formal "MOU" for development of joint venture

Lignol Energy Corporation today announced the signing of a formal Memorandum of Understanding ("MOU") between Milio International ("Milio") and LEC's subsidiary, Territory Biofuels Limited ("TBF"), for the development of a joint venture ("JV").

13 Feb 2014

Alvogen launches Inflectra into Central and Eastern Europe

Alvogen, the multinational pharmaceuticals company, today announced the launch of Inflectra (Infliximab) into Central and Eastern Europe. Inflectra, Europe's first biosimilar monoclonal antibody (mAb) therapy that has been approved for the treatment of inflammatory conditions including rheumatoid arthritis (RA), ankylosing spondylitis, Crohn's disease (CD), ulcerative colitis (UC), psoriatic arthritis (PsA) and psoriasis.

13 Feb 2014